Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. has completed a study titled ‘Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study – Kaiser Permanente Southern California.’ The study aimed to evaluate the effectiveness of two doses of the Pfizer-BioNTech BNT162b2 vaccine in preventing COVID-19-associated hospitalizations. This large-scale retrospective study is significant as it provides insights into vaccine performance against various COVID-19 strains and patient demographics.
The study tested the Pfizer-BioNTech BNT162b2 vaccine, including its bivalent and monovalent formulations. These vaccines are designed to prevent severe COVID-19 outcomes, such as hospitalization and emergency department visits.
This observational study used a case-control model with a retrospective time perspective. It involved comparing vaccinated and unvaccinated individuals to assess vaccine effectiveness in real-world settings.
The study began on May 15, 2021, with its primary completion date aligning with the study’s completion. The last update was submitted on July 28, 2025, indicating ongoing data analysis and reporting.
The completion of this study may positively impact Pfizer’s stock performance by reinforcing the efficacy of its COVID-19 vaccines. It could also influence investor sentiment positively, especially in comparison to competitors in the vaccine industry.
The study is now completed, and further details are available on the ClinicalTrials portal.